Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iclepertin Phase 2 in Schizophrenia
NCT02832037Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2016
- Primary completion
- Dec 2019
- Modality
- Classical Binding Small Molecules
- Countries
- 11
01
Overview
A Phase 2 trial of iclepertin in schizophrenia, sponsored by Boehringer Ingelheim. Started Jul 2016; status: completed.
02
Drugs
iclepertin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02832037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02832037.